Akari Therapeutics Plc (AKTX)
10.02
-0.13
(-1.28%)
USD |
NASDAQ |
Sep 03, 11:44
Akari Therapeutics Research and Development Expense (Annual) : 2.822M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 2.822M |
| December 31, 2024 | 6.986M |
| December 31, 2023 | 5.45M |
| December 31, 2022 | 11.88M |
| December 31, 2021 | 12.20M |
| December 31, 2020 | 12.19M |
| December 31, 2019 | 16.72M |
| December 31, 2018 | 11.80M |
| Date | Value |
|---|---|
| December 31, 2017 | 23.29M |
| December 31, 2016 | 17.81M |
| December 31, 2015 | 5.798M |
| December 31, 2014 | 6.391M |
| December 31, 2013 | 1.276M |
| December 31, 2012 | 1.478M |
| December 31, 2011 | 0.8398M |
| December 31, 2010 | 0.2473M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| DBV Technologies SA | 107.12M |
| Cellectis SA | 75.08M |
| argenx SE | 1.356B |
| Autolus Therapeutics Plc | 128.59M |
| Evaxion AS | 9.691M |